Search research articles
Contact Us
Filters
Showing results (241-250 of 264) with videos related to
Page
of 27
Sort By:
NPJ Breast Cancer
|
May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A Francis, Gini F Fleming, István Láng, et al.
Lancet (London, England)
|
April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
Luca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
JAMA Network Open
|
November 3, 2025
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index
Ruth M O'Regan, Yue Ren, Yi Zhang, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 264) with videos related to
Sort By:
Page
of 27
NPJ Breast Cancer
|
May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
British Journal of Cancer
|
April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A Francis, Gini F Fleming, István Láng, et al.
Lancet (London, England)
|
April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
Luca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
JAMA Network Open
|
November 3, 2025
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index
Ruth M O'Regan, Yue Ren, Yi Zhang, et al.
Page
of 27